ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 5.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,417,291 shares of the company's stock after buying an additional 71,741 shares during the quarter. Vanguard Group Inc. owned about 4.21% of ArriVent BioPharma worth $37,757,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in ArriVent BioPharma by 154.2% during the third quarter. Geode Capital Management LLC now owns 597,165 shares of the company's stock worth $14,036,000 after acquiring an additional 362,221 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of ArriVent BioPharma in the fourth quarter valued at approximately $31,000. Barclays PLC grew its position in shares of ArriVent BioPharma by 1,124.8% during the 3rd quarter. Barclays PLC now owns 41,522 shares of the company's stock worth $976,000 after buying an additional 38,132 shares in the last quarter. State Street Corp increased its position in ArriVent BioPharma by 210.4% during the 3rd quarter. State Street Corp now owns 476,809 shares of the company's stock valued at $11,205,000 after purchasing an additional 323,186 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in ArriVent BioPharma by 183.2% during the third quarter. JPMorgan Chase & Co. now owns 12,445 shares of the company's stock valued at $292,000 after buying an additional 8,050 shares during the period. Institutional investors own 9.48% of the company's stock.

ArriVent BioPharma Price Performance

AVBP stock traded up $0.24 during trading on Friday, hitting $18.14. The stock had a trading volume of 179,598 shares, compared to its average volume of 170,960. The stock has a market capitalization of $617.05 million, a P/E ratio of -7.06 and a beta of 1.66. The company's 50-day moving average price is $21.15 and its two-hundred day moving average price is $25.71. ArriVent BioPharma, Inc. has a twelve month low of $14.35 and a twelve month high of $36.37.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.18. As a group, sell-side analysts expect that ArriVent BioPharma, Inc. will post -2.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AVBP shares. B. Riley initiated coverage on shares of ArriVent BioPharma in a research note on Thursday, March 20th. They set a "buy" rating and a $37.00 price objective for the company. Guggenheim initiated coverage on shares of ArriVent BioPharma in a research report on Monday, March 10th. They issued a "buy" rating and a $45.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and set a $39.00 target price on shares of ArriVent BioPharma in a research report on Friday, March 7th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $39.00.

ArriVent BioPharma Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.